<DOC>
	<DOCNO>NCT00323557</DOCNO>
	<brief_summary>The goal clinical research study see Leukine ( R ) ( sargramostim ) improve effectiveness pneumococcal vaccine , medicine use prevent pneumococcal pneumonia , patient chronic lymphocytic leukemia ( CLL ) .</brief_summary>
	<brief_title>Immuno-Augmentation With GM-CSF Pneumococcal Vaccine Chronic Lymphocytic Leukemia Patients</brief_title>
	<detailed_description>Sargramostim ( also commonly call granulocyte macrophage colony stimulate factor - GM-CSF ) medication use stimulate bone marrow production white blood cell stem cell transplant , chemotherapy bone marrow transplant . Pneumococcal vaccine medication use prevent infection cause bacteria call Streptococcus pneumoniae . If gammaglobulins test ( test measure immunity certain infectious disease ) measure within three month study begin , blood test do receive study medication . Women able child must negative urine pregnancy test start treatment . After consent study , randomly assign ( toss coin ) receive treatment sargramostim addition pneumococcal vaccine receive pneumococcal vaccine alone ( Prevnar ) . - If randomize vaccine plus sargramostim group , receive injection sargramostim time receive pneumococcal vaccine . - If randomize vaccine alone group , receive pneumococcal vaccine first day . Blood test perform day pneumococcal vaccination , 4 week , 12 week 24 week vaccination . Each blood test require 4 teaspoon blood . These blood test measure immunity pneumococcal infection . If 6 month first vaccination body able show immunity pneumococcal infection , receive second dose either pneumococcal vaccine plus sargramostim pneumococcal vaccine alone . Your immunity check 4 week , 12 week , 24 week second dose . Only 4 teaspoon blood require test . You may remove study severe allergic reaction sargramostim and/or pneumococcal vaccine . The total maximum time study 24 month . This investigational study . Both medication use study approve FDA . Up 50 patient may treat study . All enrol M.D . Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 ) Patients complete / partial remission active Chronic lymphocytic leukemia ( CLL ) Rai stage 0 4 . 1 . Patients enter neutropenic ( PMNs &lt; 500 cells/mm3 ) receive Rituximab within 6 month . 2 . Patients enter febrile ( Temperature &gt; 38 degree C ) within 1 week . 3 . Active infection . 4 . Patients know Human immunodeficiency virus ( HIV ) infection . 5 . Known history allergy Granulocyte/ macrophage colony stimulate factor ( GMCSF ) pneumococcal vaccine . 6 . Chemotherapy Campath , fludarabine , cyclophosphamide , 4 week . 7 . Patients previously receive pneumococcal vaccine within precede 12 month . 8 . Absolute lymphocyte count le 500 cells/mm3 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Sargramostim</keyword>
	<keyword>Pneumococcal Pneumonia</keyword>
	<keyword>Pneumococcal Vaccine</keyword>
	<keyword>Prevnar</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>CLL</keyword>
</DOC>